GlassScriptPhysician profile
Andrzej S Boguszewski
NPI 1063580595
$3,765.62
in general payments reported to CMS, 2019-2025
17 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $143 · 2021: $428 · 2022: $528 · 2023: $1,822 · 2024: $260 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Travel and Lodging: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.49 |
| Travel and Lodging | $1,044.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,016.78 | 2019-2025 | Mitraclip, Portico, Xience Alpine |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.02 | 2022-2025 | Jardiance |
| Abiomed | $349.33 | 2021-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $328.55 | 2019-2024 | Farxiga |
| Medtronic, INC. | $236.24 | 2021-2025 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $114.32 | 2019-2024 | |
| Shockwave Medical, INC | $84.32 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.31 | 2019-2024 | Camzyos |
| Amgen INC. | $47.96 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $40.90 | 2019 | |
| Edwards Lifesciences Corporation | $38.83 | 2022 | |
| Livanova USA, INC. | $24.96 | 2022 | |
| Pfizer INC. | $21.83 | 2023 | |
| Teleflex LLC | $19.44 | 2023 | Manta |
| Sanofi-Aventis U.S. LLC | $18.91 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.25 | 2020 | |
| Cardiovascular Systems INC. | $1.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrzej Boguszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.